Processa Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Processa Pharmaceuticals, Inc. (PCSA) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$2.85 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-18
- Processa Pharmaceuticals, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$2.85M.
- Processa Pharmaceuticals, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$2.49M.
- Processa Pharmaceuticals, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2017 was $71.28K.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$2.85M 10-K · filed 2026-03-18 |
| 2024-12-31 | -$2.49M 10-K · filed 2026-03-18 |
| 2017-12-31 | $71.28K 10-K · filed 2020-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |